Intrust Bank NA Takes $270,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Intrust Bank NA acquired approximately 3,958 shares of DexCom, Inc. during the first quarter, valued at about $270,000.
• Several hedge funds have also increased their positions in DexCom, with ING Groep NV boosting their stake by a significant 171.3% in the same period.
• Analysts have raised price targets for DexCom, with Oppenheimer setting a new target of $102.00 and rating the stock as "outperform."

Intrust Bank NA acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,958 shares of the medical device company's stock, valued at approximately $270,000.

Other hedge funds also recently modified their holdings of the company. Ithaka Group LLC raised its holdings in shares of DexCom by 0.4% in the first quarter. Ithaka Group LLC now owns 109,670 shares of the medical device company's stock valued at $7,489,000 after purchasing an additional 448 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in DexCom by 4.4% in the first quarter. Westfield Capital Management Co. LP now owns 2,447,743 shares of the medical device company's stock worth $167,156,000 after purchasing an additional 102,142 shares during the last quarter. Geneva Capital Management LLC boosted its position in DexCom by 4.5% in the first quarter. Geneva Capital Management LLC now owns 118,072 shares of the medical device company's stock worth $8,063,000 after purchasing an additional 5,095 shares during the last quarter. Element Pointe Advisors LLC raised its stake in shares of DexCom by 7.1% in the first quarter. Element Pointe Advisors LLC now owns 4,249 shares of the medical device company's stock valued at $290,000 after buying an additional 281 shares during the period. Finally, ING Groep NV raised its stake in shares of DexCom by 171.3% in the first quarter. ING Groep NV now owns 207,798 shares of the medical device company's stock valued at $14,191,000 after buying an additional 131,195 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the completion of the transaction, the director owned 56,621 shares in the company, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,656 shares of company stock valued at $2,412,191 in the last three months. Corporate insiders own 0.32% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 target price on shares of DexCom in a research report on Friday, August 1st. Raymond James Financial boosted their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. UBS Group upped their target price on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Mizuho raised their target price on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Finally, Morgan Stanley raised their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.89.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $1.08 during midday trading on Tuesday, reaching $78.93. 1,263,514 shares of the company were exchanged, compared to its average volume of 3,902,996. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The business's fifty day moving average is $83.53 and its two-hundred day moving average is $80.20. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The stock has a market cap of $30.95 billion, a PE ratio of 54.85, a price-to-earnings-growth ratio of 1.65 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The company's quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 EPS. As a group, analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.